Transcript Power Point Presentation

Collaboration in a Public
Private Partnership in R & D
for Public good
Conference on Dispute Resolution in International
Science and Technology Collaboration
WIPO, Geneva
25 April 2005
P V Venugopal
Director (International Operations)
Medicines for Malaria Venture (MMV)
Web: www.mmv.org
MMV’s mission
“Medicines for Malaria Venture is a not-forprofit foundation dedicated to reducing the
burden of malaria in disease endemic
countries by
discovering, developing and delivering
new affordable antimalarials through
effective
public-private partnerships.”
Long road to a new medicine
Registration
Clinical Data
Analysis
Full
Development
Studies in 100-300
Patients (Phase II)
Candidate Medicine Tested in
3-10,000 Patients (Phase III)
Large Amounts of
Candidate Medicine
Synthesized
Extensive
Safety
Studies
Studies in Healthy
Volunteers Phase I
Exploratory Development
Project Team
and Plans
Candidate
Formulations
Developed
Early
Safety
Studies
Synthesis
of Compounds
Screening
Discovery
MMV’s global network of R&D
partnership
GSK at Tres Cantos
Collaboration Partners in R & D
Courtesy: GSK Tres Cantos
A Public-Private Partnership for the Discovery and
Development of Anti Malarial Drugs
MMV Input
•$$$
•Drug Profile
•Background IPR
•Link to
WHO/Policy
•Malaria
Expertise
Public
MMV Gets
Joint
R&D
Pharma
•Chemistry IPR
•Toxicology
•Know How
•Assets in Kind
•Technology
•Rights in DEC
•IPR in ‘Field’
•Drug Supply
•Return on non DEC Sales
Pharma/Bio Gets
Private
•Rights in non DEC
•IPR outside ‘Field’
•PR Benefit
•HR Benefit
•Validation of
Technology
MMV Synthetic Peroxide Project - an
example of International Partnership
Project team:
University of Nebraska
Swiss Tropical Institute
Monash University
Roche/Basilea
Ranbaxy Laboratories
+ Outsourced Support
• Cideim
• St George’s Hospital Medical
School
• Quintiles
• Pharmalytics
• Inveresk
• Unimark
• RCC
• Fulcrum
• Basilea
• Cerb
• Cerep
• Maccine
• MDS
• ICGEB
Priorities are not the same for
different partners
Pharma Companies
Profit*
University / Public Research
Institution
Recognition, more research
scientists, creation of facilities
Scientists
Fame, money, ability to add
research students to team
Public Private Partnerships
Public Health, Public good
Government
Political gains / Recognition
*MMV had to drop a Project because of the Pharma partner’s insistence on profit
‘Ideal Agreements?’
‘Prevention better than cure’ – It is better to go into
all details before finalizing the Agreement of
Collaboration, in order to avoid disputes later**
1. Create better understanding among all the partners and clarify all
aspects before the commencement of collaboration
2. Specify in the Agreement the mode of action in respect of all points of
possible causes of dispute: e.g. use ‘outside field’ of a Pharma NCE
under development, ownership of IPR created during collaboration etc.
3. Give due credit to the Scientists (generally in Universities / Academic
Institutions) whose original idea is being ‘commercialized’
4. Ensure that both the individual scientist (s) and the University /
Institution benefits from the collaboration.
5. Respect the ‘sensibilities’ of all partners in respect of multiparty
Agreements
** There are examples of Agreements which have taken over a year in negotiation. It is actually worth disputes are avoided later.
Thank you